Neuroscience biotechnology company founded in 2015 that develops diagnostic imaging agents and targeted therapies for neurodegenerative disorders, including Alzheimer’s disease and related tauopathies. Its research programs target abnormal brain proteins through PET tracers, antibodies and protein-degradation approaches. Its diagnostics branch, APN LifeSciences, works on tau imaging and AI-assisted brain-health diagnostics. APRINOIA’s October 2026 website describes continued diagnostic and therapeutic work while announcing forthcoming updates.
